The significance of this is that RVX must be getting data on ALP and eGFR for all patients in their Phase 3 trial. They can see if some are seeing improvements in ALP and eGFR. As a result, they must have an excellent idea of whether Phase 3 is going as expected.
My hunch is that they are seeing great results. Alongwith the 8 safety reviews, we most likely have a block buster drug on our hands.